Voyager Transaction
Summary
On April 23, 2025, VERAXA Biotech AG and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH), announced that they have entered into a definitive business combination agreement.The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”
On February 27, 2026, the VERAXA shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company. Both resolutions are prerequisites for the closing of the proposed business combination among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ: VACH). More information is being provided under "Events & conferences".
VERAXA Biotech AG
Dr. Christoph Antz
Chief Executive Officer
antz@veraxa.com
Voyager Acquisition Corp.
Mr. Adeel Rouf
Chief Executive Officer, and Director
adeel@voyageracq.com
Valency Communications
For Media and Investors
Mario Brkulj
Valency Communications mbrkulj@valencycomms.eu
Press releases in connection with the Voyager transaction
